Tags

Type your tag names separated by a space and hit enter

COMT inhibition in Parkinson's disease: rationale and clinical relevance.
Acta Neurol Belg. 2000 Mar; 100(1):5-7.AN

Authors

Deleu D
No affiliation info available

MeSH

Antiparkinson AgentsBenzophenonesCatechol O-Methyltransferase InhibitorsCatecholsHumansNitrilesNitrophenolsParkinson DiseaseTolcapone

Pub Type(s)

Editorial

Language

eng

PubMed ID

10779856

Citation

Deleu, D. "COMT Inhibition in Parkinson's Disease: Rationale and Clinical Relevance." Acta Neurologica Belgica, vol. 100, no. 1, 2000, pp. 5-7.
Deleu D. COMT inhibition in Parkinson's disease: rationale and clinical relevance. Acta Neurol Belg. 2000;100(1):5-7.
Deleu, D. (2000). COMT inhibition in Parkinson's disease: rationale and clinical relevance. Acta Neurologica Belgica, 100(1), 5-7.
Deleu D. COMT Inhibition in Parkinson's Disease: Rationale and Clinical Relevance. Acta Neurol Belg. 2000;100(1):5-7. PubMed PMID: 10779856.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COMT inhibition in Parkinson's disease: rationale and clinical relevance. A1 - Deleu,D, PY - 2000/4/26/pubmed PY - 2000/7/6/medline PY - 2000/4/26/entrez SP - 5 EP - 7 JF - Acta neurologica Belgica JO - Acta Neurol Belg VL - 100 IS - 1 SN - 0300-9009 UR - https://www.unboundmedicine.com/medline/citation/10779856/COMT_inhibition_in_Parkinson's_disease:_rationale_and_clinical_relevance_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -